Safety and efficacy of fosaprepitant in children and adolescents for treating chemotherapy induced nausea and vomiting

Trial Profile

Safety and efficacy of fosaprepitant in children and adolescents for treating chemotherapy induced nausea and vomiting

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Fosaprepitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top